Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for ventricular arrhythmia event reduction in patients with heart failure and type 2 diabetes
MOH_2017-06-30_000576Phase 4Not yet recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in ventricular arrhythmia (VA), heart failure (HF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Ventricular arrhythmia event rate. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
ventricular arrhythmia (VA)heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2017-06-30_000576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-30_000576.